Highlights
- Careteq (ASX:CTQ) reported developments during 2026.
- Careteq completed the sale of its Embedded Health Solutions Subsidiary in April 2026.
- In August 2026 the company reported FY26 results and released its annual report.
- The November 18, 2026 share price was AUD 0.010, up 11.11%.
Careteq operates in health technology, including medication-management and referral-related services with an emphasis on clinical governance. Careteq (ASX:CTQ) closed at AUD 0.010 on November 18, 2026, gaining 11.11% during the session. Its 2026 developments included the disposal of Embedded Health Solutions, continued ASX Quotation following a review of post-sale plans and organisational arrangements supporting Home Medicines Review Referrals.
Careteq Business and Operations
Careteq operates in clinical health technology, including medication management and referral-related services, with an emphasis on AI-enabled healthcare solutions and clinical governance. The sale of Embedded Health Solutions changed the scope of the business, so descriptions of continuing operations should use the post-sale structure.
Careteq 2026 Company Updates
Careteq completed the sale of its Embedded Health Solutions subsidiary in April 2026. In July it reported that the ASX had confirmed continued quotation of its securities following consideration of its post-divestment operating plans. These disclosures are significant to the shape of its remaining activities. The ASX decision concerned continued quotation following its review of post-divestment plans, not confirmation of future earnings.
Careteq Financial and Operational Context
In August 2026 the company reported FY26 results and released its annual report. Earlier that month it established an advisory board to support its Home Medicines Review Referrals activities. It also released June-quarter activities and cash-flow commentary and announced a new non-executive director in July. The advisory board relates to referral activities in the remaining business and does not itself quantify future revenue.
Industry Conditions and Key Risks
After a business disposal, historical group Revenue and expenses may not directly describe continuing operations. Execution depends on referral volumes, integration of systems, clinical governance, data privacy and funding of ongoing development. Following a disposal, comparability of group figures depends on separating discontinued or disposed activity from the remaining services.
What to Watch Next
Later quarterly results will be important for separating recurring activity in Careteq’s remaining operations from the effects of its April subsidiary disposal. Disclosures on Home Medicines Review Referrals, referral volumes and clinical governance arrangements may clarify how the post-sale business operates. Readers can also assess revenue recognition, operating expenses and available cash in the next reports. The ASX quotation decision resolved a particular listing matter; it did not by itself establish future operating performance.
Key Insights
Careteq (ASX:CTQ) completed a subsidiary sale and outlined its post-divestment operating plans during 2026. Its referral-related activities and advisory-board arrangements provide context for the remaining business, but historical consolidated results may include operations no longer owned. Subsequent continuing-operations figures, cash-flow disclosures and evidence of repeatable service activity will be central to evaluating its progress.






Please wait processing your request...